Business
Following the Filing for the Opening of Reorganization Proceedings, Poxel Announces Changes to Its Corporate Governance
LYON, France, August 01, 2025--Regulatory News: POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, announces significant changes within the Board of Directors.
About this update from Poxel Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":256,"url":"https://media.zenfs.com/en/business-wire.com/e5a3c9dcdf20b1bfb629a9f06f2099a0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KwSiT.seuxzzWVgYcIm1lQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxMjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e5a3c9dcdf20b1bfb629a9f06f2099a0","width":480,"height":256}},"lazy":false},{"type":"text","content":"LYON, France, August 01, 2025--(BUSINESS WIRE)--Regulatory News:","length":64,"tagName":"p"},{"type":"text","content":"POXEL SA (Euronext : POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including Metabolic dysfunction-Associated SteatoHepatitis (MASH) and rare metabolic disorders, announces significant changes within the Board of Directors.","length":337,"tagName":"p"},{"type":"text","content":"As mentioned in the press release dated July 29, 2025 following the agreement signed by Poxel and its directors with the senior creditor of the Company, and in the context of the filing for the insolvency ("déclaration de cessation des paiements") and request for opening of reorganization proceedings ("redressement judiciaire") with the Court for Economic Activities of Lyon, all the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn and Mr. Khoso Baluch, have submitted their resignations with immediate effect as of July 31, 2025.","length":595,"tagName":"p"},{"type":"text","content":"At its meeting on July 31, 2025, the Board of Directors of the Company decided to replace them individually by co-optation with immediate effect by the following new directors:","length":176,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Ms. Sophie Jacq Lapointe;","length":25,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Mr. Nicolas Trouche;","length":20,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Mr. Amit Kohli;","length":15,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Mr. Alexandre Bragadir.","length":23,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":83,"olType":false},{"type":"tex...